In order to optimize overall patient outcomes, clinicians need to understand the evidence behind the current guidelines’ recommendations, the rationale for appropriate treatment selection, and the management of any treatment- or multiple myeloma-specific adverse events.

With careful risk assessment, monitoring, and prophylactic treatment, the cardiovascular adverse events associated with multiple myeloma (MM) treatments can be prevented or identified and managed at an early stage. To optimize the management of patients with multiple myeloma and cardiac comorbidities, it is important for clinicians to learn how to recognize these risks and implement appropriate management strategies.

Education about individualizing treatment strategies will assist healthcare providers to make informed decisions about incorporating immunotherapies into treatment regimens. 

Clinicians must understand the treatment evolution and guidelines for when to administer two-, three-, or four drug regimens as initial or subsequent therapy in context of the patient's therapeutic and disease history. In addition, it is important for clinicians to educate patients about their different treatment options (e.g., administration and adverse events) and discuss patient preferences and individual circumstances that may affect treatment recommendations.

In order to optimize overall patient outcomes, clinicians need to understand the evidence behind the current guidelines’ recommendations, the rationale for appropriate treatment selection, and the management of any treatment- or multiple myeloma-specific adverse events.

To navigate through the complex treatment landscape, physicians and other oncology care providers must understand the evolving therapeutic options and guidelines for administration of the available therapies in the context of the patient's therapeutic and disease history. The increasing complexity of myeloma treatment warrants rigorous efforts to provide adequate supportive care and preserve the quality of life of patients.

Pharmacists should be aware of the new data and recommendations surrounding this novel agent and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.

The information presented in this talk will address the long-term effects of CAR T-cell therapy, including HLH/MAS, B-cell aplasia, and prolonged cytopenias. Nurses will learn how to recognize signs/symptoms of these effects and how to manage them in order to educate patients and provide ideal care to patients undergoing CAR T-cell therapy.

In order to optimize patient outcomes, clinicians need to understand the evidence behind the current recommendations in the guidelines, the rationale for appropriate treatment selection, management of any treatment- or MM-specific adverse events, and emerging strategies.

Pharmacists should be aware of the new data and recommendations surrounding this novel agent and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.